Price Alert: Shares of GT (GTBP) Trade 5.14% Higher at Midday June 22

Equities Staff  |

GT Biopharma Inc (NASDAQ: GTBP) has risen $0.15 (5.14%) and is currently sitting at $3.10, as of 11:57:34 est on June 22.

163,393 shares have been traded today.

The Company is up 1.74% over the last 5 days and shares have risen 9.36% over the last 30 days.

GT anticipates its next earnings on 2022-08-12.

For technical charts, analysis, and more on GT visit the company profile.

About GT Biopharma Inc

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology.

To get more information on GT Biopharma Inc and to follow the company's latest updates, you can visit the company's profile page here: GT Biopharma Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content